Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)

Summary

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of the neurokinin type 2 receptor antagonist Ibodutant in improving IBS-D symptoms.

Timeline

Start

2010-10

Primary completion

2012-05

Completion

2012-07

Outcome

Met primary endpoint

paper ibodutant 10 mg demonstrated significant superiority over placebo in females (p=0.003) PMID 27196574 ↗

Publications

• Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA; Iris-2 investigators. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut. 2017 Aug;66(8):1403-1413. doi: 10.1136/gutjnl-2015-310683. Epub 2016 Apr 15.

Drugs

Indications